{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:37:12Z","timestamp":1790329032506,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008273","name":"Novartis Research Foundation","doi-asserted-by":"crossref","award":["Virtual twinning for intelligent"],"award-info":[{"award-number":["Virtual twinning for intelligent"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008273","name":"Novartis Research Foundation","doi-asserted-by":"crossref","award":["personalized transdermal drug delivery"],"award-info":[{"award-number":["personalized transdermal drug delivery"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"crossref"}]},{"name":"OPO Foundation","award":["Digital human avatars help tailor transdermal pain management (TREATME)"],"award-info":[{"award-number":["Digital human avatars help tailor transdermal pain management (TREATME)"]}]},{"name":"Empa - Swiss Federal Laboratories for Materials Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fentanyl transdermal therapy is a suitable treatment for moderate-to-severe cancer-related pain. The inter-individual variability of the patients leads to different therapy responses. This study aims to determine the effect of physiological features on the achieved pain relief. Therefore, a set of virtual patients was developed by using Markov chain Monte Carlo (MCMC) based on actual patient data. The members of this virtual population differ by age, weight, gender, and height. Tailored digital twins were developed using these correlated, individualized parameters to propose a personalized therapy for each patient. It was shown that patients of different ages, weights, and gender have significantly different fentanyl blood uptake, plasma fentanyl concentration, pain relief, and ventilation rate. In the digital twins, we included the virtual patients\u2019 response to the treatment, namely, pain relief. Therefore, the digital twin was able to adjust the therapy in silico to have more efficient pain relief. By implementing digital-twin-assisted therapy, the average pain intensity decreased by 16% compared to conventional therapy. The median time without pain increased by 23\u00a0h over 72\u00a0h. Therefore, the digital twin can be successfully used in individual control of transdermal therapy to reach higher pain relief and maintain steady pain relief.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>(Created with BioRender.com)<\/jats:p>","DOI":"10.1007\/s13346-023-01305-y","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T09:04:24Z","timestamp":1678439064000},"page":"2272-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["An individualized digital twin of a patient for transdermal fentanyl therapy for chronic pain management"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8125-4939","authenticated-orcid":false,"given":"Flora","family":"Bahrami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 Michel","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelijne","family":"De Nys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Defraeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"1305_CR1","doi-asserted-by":"crossref","unstructured":"Han Y, Yan W, Zheng Y, Khan MZ, Yuan K, Lu L.\u00a0The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies.\u00a0Transl Psychiatry, no. September 2018, 2019.","DOI":"10.1038\/s41398-019-0625-0"},{"issue":"5","key":"1305_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/15563659509013752","volume":"33","author":"A Poklis","year":"1995","unstructured":"Poklis A. Fentanyl: a review for clinical and analytical toxicologists. J Toxicol Clin Toxicol. 1995;33(5):439\u201347.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"8","key":"1305_CR3","first-page":"581","volume":"10","author":"MA Clotz","year":"1991","unstructured":"Clotz MA, Nahata MC. Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm. 1991;10(8):581\u201393.","journal-title":"Clin Pharm"},{"key":"1305_CR4","doi-asserted-by":"crossref","unstructured":"Shinohara A, Andoh T, Saiki I, Kuraishi Y.\u00a0Analgesic e ff ects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice. Eur J Pharmacol.\u00a02018;833(2017):275\u2013282.","DOI":"10.1016\/j.ejphar.2018.06.008"},{"issue":"8","key":"1305_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/0973-1482.171368","volume":"14","author":"D-D Wang","year":"2018","unstructured":"Wang D-D, Ma T-T, Zhu H-D, Peng C-B. Transdermal fentanyl for cancer pain: trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther. 2018;14(8):14.","journal-title":"J Cancer Res Ther"},{"issue":"12","key":"1305_CR6","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/PCC.0000000000002163","volume":"20","author":"C Tang","year":"2019","unstructured":"Tang C, Poloyac SM. A Modeling-based approach to estimate fentanyl pharmacokinetics in obese critically ill children. Pediatr Crit Care Med. 2019;20(12):1208\u20139.","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"1305_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41598-019-51279-6","volume":"9","author":"MJP Geist","year":"2019","unstructured":"Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. Sci Rep. 2019;9(1):6\u201311.","journal-title":"Sci Rep"},{"issue":"2","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s10237-019-01219-0","volume":"19","author":"J Chen","year":"2020","unstructured":"Chen J, Weihs D, Vermolen FJ. Computational modeling of therapy on pancreatic cancer in its early stages. Biomech Model Mechanobiol. 2020;19(2):427\u201344.","journal-title":"Biomech Model Mechanobiol"},{"key":"1305_CR9","doi-asserted-by":"crossref","unstructured":"Rostami AA, Rostami AA. Computational modeling of aerosol deposition in respiratory tract\u202f: a review computational modeling of aerosol deposition in respiratory tract\u202f: a review. 2009;8378.","DOI":"10.1080\/08958370802448987"},{"key":"1305_CR10","doi-asserted-by":"crossref","unstructured":"Pak J, Chen ZJ, Sun K, Przekwas A, Walenga R, Fan J.\u00a0Computational modeling of drug transport across the in vitro cornea. Comput Biol Med.\u00a02018;92(2017):139\u2013146.","DOI":"10.1016\/j.compbiomed.2017.11.009"},{"key":"1305_CR11","doi-asserted-by":"crossref","unstructured":"Kashkooli FM, Soltani M, Momeni MM, Rahmim A.\u00a0Enhanced drug delivery to solid tumors via drug-loaded nanocarriers\u202f: an image-based computational framework. 2021;11.","DOI":"10.3389\/fonc.2021.655781"},{"key":"1305_CR12","doi-asserted-by":"crossref","unstructured":"Dillon T,\u00a0et al.\u00a0Computational modeling of a low-cost fluidic oscillator for use in an educational respiratory simulator. 2021;2000112.","DOI":"10.1002\/anbr.202000112"},{"key":"1305_CR13","doi-asserted-by":"crossref","unstructured":"Moradi F, Soltani M, Masoud M. Journal of drug delivery science and technology computational modeling of drug delivery to solid tumors\u202f: a pilot study based on a real image. J Drug Deliv Sci Technol.\u00a02021;62(2020):102347.","DOI":"10.1016\/j.jddst.2021.102347"},{"key":"1305_CR14","doi-asserted-by":"crossref","unstructured":"Defraeye T, Bahrami F, Ding L, Malini RI, Terrier A, Rossi RM.\u00a0Predicting transdermal fentanyl delivery using mechanistic simulations for tailored therapy. Front Pharmacol.\u00a02020;11.","DOI":"10.3389\/fphar.2020.585393"},{"key":"1305_CR15","doi-asserted-by":"crossref","unstructured":"Defraeye T, Bahrami F, Rossi RM. Inverse mechanistic modeling of transdermal drug delivery for fast identification of optimal model parameters. 2021;12:1\u201315.","DOI":"10.3389\/fphar.2021.641111"},{"key":"1305_CR16","doi-asserted-by":"crossref","unstructured":"Becker S, Zorec B, Miklav\u010di\u010d D, Pav\u0161elj N.\u00a0Mathematical biosciences transdermal transport pathway creation\u202f: electroporation pulse order \u02c7 ic. 2014;257:60\u201368.","DOI":"10.1016\/j.mbs.2014.07.001"},{"key":"1305_CR17","doi-asserted-by":"crossref","unstructured":"Neumann D, Kohlbacher O, Merkwirth C, Lengauer T.\u00a0A fully computational model for predicting percutaneous drug absorption. 2006:424\u2013429.","DOI":"10.1021\/ci050332t"},{"key":"1305_CR18","doi-asserted-by":"crossref","unstructured":"Lacount TD,\u00a0et al.\u00a0Modeling temperature-dependent dermal absorption and clearance for transdermal and topical drug applications. 2020:1\u201313.","DOI":"10.1208\/s12248-020-00451-2"},{"key":"1305_CR19","doi-asserted-by":"crossref","unstructured":"Dalvi M, Kharat P, Thakor P, Bhavana V, Singh SB, Mehra NK.\u00a0Panorama of dissolving microneedles for transdermal drug delivery. Life Sci.\u00a02021;284:119877.","DOI":"10.1016\/j.lfs.2021.119877"},{"issue":"2","key":"1305_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijpharm.2017.05.066","volume":"533","author":"N Filipovic","year":"2017","unstructured":"Filipovic N, Saveljic I, Rac V, Graells BO, Bijelic G. Computational and experimental model of transdermal iontophorethic drug delivery system. Int J Pharm. 2017;533(2):383\u20138.","journal-title":"Int J Pharm"},{"issue":"2","key":"1305_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.addr.2012.10.009","volume":"65","author":"A Naegel","year":"2013","unstructured":"Naegel A, Heisig M, Wittum G. Detailed modeling of skin penetration-an overview. Adv Drug Deliv Rev. 2013;65(2):191\u2013207.","journal-title":"Adv Drug Deliv Rev"},{"key":"1305_CR22","doi-asserted-by":"crossref","unstructured":"Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M.\u00a0Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. 2007;321(2):598\u2013607.","DOI":"10.1124\/jpet.106.115972"},{"issue":"1","key":"1305_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40262-012-0016-7","volume":"52","author":"J L\u00f6tsch","year":"2013","unstructured":"L\u00f6tsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Pharmacokinetics of non-intravenous formulations of fentanyl. Clin Pharmacokinet. 2013;52(1):23\u201336.","journal-title":"Clin Pharmacokinet"},{"key":"1305_CR24","doi-asserted-by":"crossref","unstructured":"Kovar L, et al.\u00a0Physiologically-based pharmacokinetic (PBPK) modeling providing insights into fentanyl pharmacokinetics in adults and pediatric patients. 2020;450:1\u201320.","DOI":"10.3390\/pharmaceutics12100908"},{"key":"1305_CR25","doi-asserted-by":"publisher","first-page":"10489","DOI":"10.1021\/jacs.9b04872","volume":"141","author":"LC Smith","year":"2019","unstructured":"Smith LC, et al. Monoclonal antibodies for combating synthetic opioid intoxication. J Am Chem Soc. 2019;141:10489\u2013503.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"1305_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/10717544.2022.2050846","volume":"29","author":"F Bahrami","year":"2022","unstructured":"Bahrami F, Rossi RM, Defraeye T. Predicting transdermal fentanyl delivery using physics-based simulations for tailored therapy based on the age. Drug Deliv. 2022;29(1):950\u201369.","journal-title":"Drug Deliv"},{"issue":"3","key":"1305_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0304-3959(92)90034-9","volume":"50","author":"DFJ Zech","year":"1992","unstructured":"Zech DFJ, Grond SUA, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain. 1992;50(3):293\u2013301.","journal-title":"Pain"},{"key":"1305_CR28","doi-asserted-by":"crossref","unstructured":"Defraeye T, Bahrami F, Ding L, Malini RI, Terrier A, Rossi RM.\u00a0Predicting transdermal fentanyl delivery using mechanistic simulations for personalized therapy. J Control Release.\u00a02020.","DOI":"10.1101\/2020.06.16.154195"},{"key":"1305_CR29","doi-asserted-by":"crossref","unstructured":"Defraeye T, Bahrami F, Rossi RM. Inverse mechanistic modeling of transdermal drug delivery for fast identification of optimal model parameters.\u00a0bioRxiv.\u00a02020:2020.12.11.420836.","DOI":"10.3389\/fphar.2021.641111"},{"issue":"6","key":"1305_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1365-2125.2011.03925.x","volume":"71","author":"DFB Wright","year":"2011","unstructured":"Wright DFB, Winter HR, Duffull SB. Understanding the time course of pharmacological effect: A PKPD approach. Br J Clin Pharmacol. 2011;71(6):815\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"1305_CR31","doi-asserted-by":"crossref","unstructured":"Cot\u00e9 CJ, Lerman J, Ward RM, Lugo RA, Goudsouzian N.\u00a0Drug and pharmacokinetics and pharmacology of drugs used in children Chapter. 2009:89\u2013146.","DOI":"10.1016\/B978-141603134-5.50010-X"},{"issue":"4","key":"1305_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/srt.12132","volume":"20","author":"E Boireau-Adamezyk","year":"2014","unstructured":"Boireau-Adamezyk E, Baillet-Guffroy A, Stamatas GN. Age-dependent changes in stratum corneum barrier function. Ski Res Technol. 2014;20(4):409\u201315.","journal-title":"Ski Res Technol"},{"issue":"1","key":"1305_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/srt.12294","volume":"23","author":"A Firooz","year":"2017","unstructured":"Firooz A, Rajabi-Estarabadi A, Zartab H, Pazhohi N, Fanian F, Janani L. The influence of gender and age on the thickness and echo-density of skin. Ski Res Technol. 2017;23(1):13\u201320.","journal-title":"Ski Res Technol"},{"key":"1305_CR34","doi-asserted-by":"crossref","unstructured":"Robert L, Robert A. Physiologie du vieillissement cutane. 2009;57:336\u2013341.","DOI":"10.1016\/j.patbio.2008.09.007"},{"issue":"1","key":"1305_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0086637","volume":"9","author":"JGB Derraik","year":"2014","unstructured":"Derraik JGB, et al. Effects of age, gender, BMI, and anatomical site on skin thickness in children and adults with diabetes. PLoS ONE. 2014;9(1):1\u20136.","journal-title":"PLoS ONE"},{"issue":"6","key":"1305_CR36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/bcp.12903","volume":"81","author":"SL Van Driest","year":"2016","unstructured":"Van Driest SL, et al. Pragmatic pharmacology: population pharmacokinetic analysis of fentanyl using remnant samples from children after cardiac surgery. Br J Clin Pharmacol. 2016;81(6):1165\u201374.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1305_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/A:1026194618660","volume":"30","author":"S Bj\u00f6rkman","year":"2003","unstructured":"Bj\u00f6rkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J Pharmacokinet Pharmacodyn. 2003;30(4):285\u2013307.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"1","key":"1305_CR38","first-page":"159","volume":"240","author":"JC Scott","year":"1987","unstructured":"Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther. 1987;240(1):159\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"1305_CR39","unstructured":"Holmberg K, Kong J, Lee S, Horwitz J.\u00a0The effects of applied local heat on transdermal drug delivery systems.\u00a02008."},{"issue":"3","key":"1305_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2710.1997.94875948.x","volume":"22","author":"RS Miller","year":"1997","unstructured":"Miller RS, Peterson GM, McLean S, M\u00f6ller C. Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium. J Clin Pharm Ther. 1997;22(3):197\u2013205.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"1305_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","volume":"81","author":"A Yassen","year":"2007","unstructured":"Yassen A, et al. Mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther. 2007;81(1):50\u20138.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1305_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40272-013-0029-1","volume":"15","author":"E Encinas","year":"2013","unstructured":"Encinas E, Calvo R, Lukas JC, Vozmediano V, Rodriguez M, Suarez E. A predictive pharmacokinetic\/pharmacodynamic model of fentanyl for analgesia\/sedation in neonates based on a semi-physiologic approach. Pediatr Drugs. 2013;15(3):247\u201357.","journal-title":"Pediatr Drugs"},{"key":"1305_CR43","unstructured":"US Food and Drug Administration. Duragesic Label. 2005."},{"issue":"1","key":"1305_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003495-199753010-00011","volume":"53","author":"W Jeal","year":"1997","unstructured":"Jeal W, Benfield P. Transdermal fentanyl - a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53(1):109\u201338.","journal-title":"Drugs"},{"issue":"2","key":"1305_CR45","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/00000542-199902000-00034","volume":"90","author":"PWH Peng","year":"1999","unstructured":"Peng PWH, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. J Am Soc Anesthesiol. 1999;90(2):576\u201399.","journal-title":"J Am Soc Anesthesiol"},{"issue":"7","key":"1305_CR46","first-page":"447","volume":"58","author":"M Schulz","year":"2003","unstructured":"Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58(7):447\u201374.","journal-title":"Pharmazie"},{"key":"1305_CR47","unstructured":"Ma Z.\u00a0Pharmacokinetics of fentanyl in epileptic patients during concomitant therapy with phenytoin or carbamazepine.\u00a0Doctoral dissertation, Tufts University-Graduate School of Biomedical Sciences. 2018."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01305-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-023-01305-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-023-01305-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T10:21:01Z","timestamp":1690539661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-023-01305-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s13346-023-01305-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.07.25.22277536","asserted-by":"object"}]},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"28 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}